Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$68.00

-7.99 (-10.51%)

07:42
11/25/16
11/25
07:42
11/25/16
07:42

Eli Lilly price target lowered to $70 from $82 at UBS

UBS analyst Marc Goodman lowered his price target on Eli Lilly to $70 from $82 following the halt of its solanezumab drug trial for Alzheimer's. The analyst removed his sales estimates for solanezumab and said that without its contribution he is less optimistic for top-line growth. Goodman recommends investors stay on the sidelines and reiterated his Neutral rating on Eli Lilly shares.

  • 04

    Dec

LLY Eli Lilly
$68.00

-7.99 (-10.51%)

11/23/16
COWN
11/23/16
NO CHANGE
Target $85
COWN
Outperform
Eli Lilly price target lowered to $85 from $100 at Cowen
Cowen analyst Steve Scala eliminated solanezumab from his Eli Lilly model which lowered 2018 earnings forecasts to $4.15 from $4.35 and 2019 to $4.75 from $5.30 and a reduction in his price target to $85 from $100. Despite the solanezumab setback, Scala said Outperform rated Eli Lilly has a number of promising new drugs and late-stage agents poised to launch over the next several years that given him confidence in sales and earnings growth prospects.
11/23/16
BMOC
11/23/16
DOWNGRADE
BMOC
Market Perform
Eli Lilly downgraded to Market Perform from Outperform at BMO Capital
11/23/16
JMPS
11/23/16
NO CHANGE
JMPS
Axovant not impacted by Lilly's solanezumab failure, says JMP Securities
JMP Securities analyst Jason Butler said Axovant Sciences (AXON) is not impacted by Eli Lilly's (LLY) solanezumab. The analyst said solanezumab has a very different mechanism of action, and unlike solanezumab, Axovant's has already prospectively demonstrated statistically significant improvements in cognition and function in a pivotal trial. Butler recommends buying Axovant on weakness and reiterates his Outperform rating and $36 price target.
11/25/16
RHCO
11/25/16
NO CHANGE
Target $101
RHCO
Buy
Eli Lilly price target lowered to $101 from $107 at SunTrust
SunTrust analyst John Boris removed solanezumab, which he had viewed as a "high risk/high reward" asset, from his model after the company reported a Phase 3 study showed that the drug failed to slow loss of cognitive ability in patients with mild Alzheimer's disease. Boris cut his price target on Lilly shares to $101 from $107, but recommends taking advantage of weakness in the shares, on which he keeps a Buy rating.

TODAY'S FREE FLY STORIES

09:25
01/22/18
01/22
09:25
01/22/18
09:25
General news
IMF revised its global growth outlook higher, in part on U.S. tax cuts »

IMF revised its global…

PAYC

Paycom

, ALRM

Alarm.com

$38.73

-0.7 (-1.78%)

09:25
01/22/18
01/22
09:25
01/22/18
09:25
Conference/Events
Jefferies software analyst holds an analyst/industry conference call »

Software Analyst DiFucci…

PAYC

Paycom

ALRM

Alarm.com

$38.73

-0.7 (-1.78%)

CA

CA Technologies

$34.07

-0.12 (-0.35%)

RHT

Red Hat

ORCL

Oracle

SSNC

SS&C

$49.98

0.04 (0.08%)

VMW

VMware

CTXS

Citrix

$92.72

1.34 (1.47%)

MSFT

Microsoft

$90.00

-0.1 (-0.11%)

SYMC

Symantec

$27.46

0.21 (0.77%)

PANW

Palo Alto Networks

APTI

Apptio

$24.79

0.56 (2.31%)

CHKP

Check Point

$104.48

1.28 (1.24%)

NICE

Nice

$93.60

-0.23 (-0.25%)

SPLK

Splunk

$89.94

-1.49 (-1.63%)

RNG

RingCentral

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 12

    Feb

  • 26

    Feb

  • 27

    Feb

DCIX

Diana Containerships

$3.24

0.09 (2.86%)

09:23
01/22/18
01/22
09:23
01/22/18
09:23
Hot Stocks
Diana Containerships sells two post-Panamax container vessels for $22M »

Diana Containerships has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAA

CalAtlantic

, LEN

Lennar

09:23
01/22/18
01/22
09:23
01/22/18
09:23
Recommendations
CalAtlantic, Lennar analyst commentary  »

CalAtlantic price target…

CAA

CalAtlantic

LEN

Lennar

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

09:21
01/22/18
01/22
09:21
01/22/18
09:21
Downgrade
South Jersey Industries rating change  »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

KBH

KB Home

09:20
01/22/18
01/22
09:20
01/22/18
09:20
Recommendations
KB Home analyst commentary  »

KB Home price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

09:20
01/22/18
01/22
09:20
01/22/18
09:20
General news
U.S. Producer Sentiment Tailwinds Extend Into 2018: »

U.S. Producer Sentiment…

TOL

Toll Brothers

09:19
01/22/18
01/22
09:19
01/22/18
09:19
Recommendations
Toll Brothers analyst commentary  »

Toll Brothers price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$179.64

4.16 (2.37%)

, HAL

Halliburton

09:19
01/22/18
01/22
09:19
01/22/18
09:19
Hot Stocks
On The Fly: Pre-market Movers »

UP AFTER EARNINGS: Wynn…

WYNN

Wynn Resorts

$179.64

4.16 (2.37%)

HAL

Halliburton

PETS

PetMed Express

$53.24

2.67 (5.28%)

OPB

Opus Bank

$28.70

0.05 (0.17%)

BCRX

BioCryst

$5.59

-0.09 (-1.58%)

IDRA

Idera Pharmaceuticals

$2.55

0.145 (6.03%)

ANF

Abercrombie & Fitch

AAPL

Apple

$178.46

-0.8 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 01

    Feb

CYTX

Cytori Therapeutics

$0.40

-0.0188 (-4.48%)

09:19
01/22/18
01/22
09:19
01/22/18
09:19
Hot Stocks
Cytori Therapeutics completes enrollment in Habeo trial for scleroderma »

Cytori Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBS

UBS

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Periodicals
UBS to start moving jobs in early 2018 ahead of Brexit, Telegraph reports »

UBS will begin shifting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

PHM

PulteGroup

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Recommendations
PulteGroup analyst commentary  »

PulteGroup price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

RF

Regions Financial

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Upgrade
Regions Financial rating change  »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Options
Overnight activity included 111 trades in SPX and 29 trades in VIX »

111 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RF

Regions Financial

09:17
01/22/18
01/22
09:17
01/22/18
09:17
Upgrade
Regions Financial rating change  »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

09:16
01/22/18
01/22
09:16
01/22/18
09:16
Recommendations
D.R. Horton analyst commentary  »

D.R. Horton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

SDR

SandRidge Mississippian Trust II

09:16
01/22/18
01/22
09:16
01/22/18
09:16
Hot Stocks
SandRidge Mississippian Trust II receives NYSE notice on listing standards »

SandRidge Mississippian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:15
01/22/18
01/22
09:15
01/22/18
09:15
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

HAL

Halliburton

09:14
01/22/18
01/22
09:14
01/22/18
09:14
Hot Stocks
Halliburton says expects improved utilization to drive margin growth »

Sees boosting frack…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FE

FirstEnergy

09:14
01/22/18
01/22
09:14
01/22/18
09:14
Hot Stocks
FirstEnergy receives $2.5B equity investment »

FirstEnergy announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

DNKN

Dunkin' Brands

$64.56

-0.53 (-0.81%)

09:13
01/22/18
01/22
09:13
01/22/18
09:13
Upgrade
Dunkin' Brands rating change  »

William Blair upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VC

Visteon

$131.85

-0.54 (-0.41%)

09:13
01/22/18
01/22
09:13
01/22/18
09:13
Recommendations
Visteon analyst commentary  »

Visteon price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$65.75

0.65 (1.00%)

09:12
01/22/18
01/22
09:12
01/22/18
09:12
Conference/Events
Mellanox management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

IOVA

Iovance Biotherapeutics

$10.70

1.075 (11.17%)

09:12
01/22/18
01/22
09:12
01/22/18
09:12
Recommendations
Iovance Biotherapeutics analyst commentary  »

Iovance Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.